Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer

Clinical Cancer Research

Volumn 20, Issue 23, 2014, Pages 6163-6174

  Suryawanshi, Swati ^a   Huang, Xin ^a   Elishaev, Esther ^a,b   Budiu, Raluca A ^a   Zhang, Lixin ^a   Kim, SungHwan ^c   Donnellan, Nicole ^b   Mantia Smaldone, Gina ^d   Ma, Tianzhou ^c   Tseng, George ^c   Lee, Ted ^b   Mansuria, Suketu ^b   Edwards, Robert P ^a,b   Vlad, Anda M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RNA; COMPLEMENT COMPONENT C7;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BENIGN TUMOR; CANCER CLASSIFICATION; CELL MUTANT; CELL PROLIFERATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENDOMETRIOSIS; ENDOMETRIOSIS ASSOCIATED OVARIAN CANCER; EPITHELIUM CELL; FEMALE; GENE EXPRESSION ASSAY; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOGENETICS; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PELVIC INFLAMMATORY DISEASE; TUMOR MICROENVIRONMENT; UPREGULATION; AGED; ANIMAL; CELL TRANSFORMATION; CLUSTER ANALYSIS; COMPLEMENT ACTIVATION; COMPLICATION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IMMUNOLOGY; IMMUNOSURVEILLANCE; METABOLISM; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; RISK FACTOR;

ADULT; AGED; ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; COMPLEMENT ACTIVATION; COMPLEMENT C7; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; ENDOMETRIOSIS; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOLOGIC SURVEILLANCE; MICE; MIDDLE AGED; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 84918513408     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1338     Document Type: Article

References (46)

1. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71.
2. Wu Y, Antony S, Meitzler JL, Doroshow JH. Molecular mechanisms underlying chronic inflammation-associated cancers. Cancer Lett 2014;345:164-73.
3. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376-88.
4. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211:26-35.
5. Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, et al. Transformation of the fallopian tube secretory epithelium leads to highgrade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 2013;24:751-65.
6. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012;13:385-94.
7. Giudice LC. Clinical practice. endometriosis. N Engl J Med 2012;362:2389-98.
8. Brown J, Farquhar C. Endometriosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev 2014;3: CD009590.
9. Nishida M, Watanabe K, Sato N, Ichikawa Y. Malignant transformation of ovarian endometriosis. Gynecol Obstet Invest 2000;50 Suppl 1:18-25
10. Seidman JD. Prognostic importance of hyperplasia and atypia in endometriosis. Int J Gynecol Pathol 1996;15:1-9.
11. Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010;330:228-31.
12. Samartzis EP, Samartzis N, Noske A, Fedier A, Caduff R, Dedes KJ, et al. Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation? Mod Pathol 2012;25:885-92
13. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-43.
14. Fukunaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 1997;30:249-55.
15. Varma R, Rollason T, Gupta JK, Maher ER. Endometriosis and the neoplastic process. Reproduction 2004;127:293-304.
16. Vlahos NF, Economopoulos KP, Fotiou S. Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer. Best Pract Res Clin Obstet Gynaecol 2010;24:39-50.
17. Khan KN, Kitajima M, Hiraki K, Fujishita A, Sekine I, Ishimaru T, et al. Toll-like receptors in innate immunity: role of bacterial endotoxin and toll-like receptor 4 in endometrium and endometriosis. Gynecol Obstet Invest 2009;68:40-52.
18. Hou Z, Sun L, Gao L, Liao L, Mao Y, Liu J. Cytokine array analysis of peritoneal fluid between women with endometriosis of different stages and those without endometriosis. Biomarkers 2009;14:604-18.
19. Gupta S, Agarwal A, Sekhon L, Krajcir N, Cocuzza M, Falcone T. Serum and peritoneal abnormalities in endometriosis: potential use as diagnostic markers. Minerva Ginecol 2006;58:527-51.
20. Borrelli GM, Abrao MS, Mechsner S. Can chemokines be used as biomarkers for endometriosis? A systematic review. Hum Reprod 2014;29:253-66.
21. Budiu RA, Elishaev E, Brozick J, Lee M, Edwards RP, Kalinski P, et al. Immunobiology of human mucin 1 in a preclinical ovarian tumor model. Oncogene 2013;32:3664-75.
22. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000;21:585-91.
23. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139-40.
24. Ness RB, Modugno F. Endometriosis as a model for inflammationhormone interactions in ovarian and breast cancers. Eur J Cancer 2006;42:691-703.
25. Alcazar JL, Guerriero S, Ajossa S, Parodo G, Piras B, Peiretti M, et al. Extragenital endometrial stromal sarcoma arising in endometriosis. Gynecol Obstet Invest 2012;73:265-71.
26. Koninckx PR, Meuleman C, Demeyere S, Lesaffre E, Cornillie FJ. Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. Fertil Steril 1991;55:759-65.
27. Yang Q, Wang H, Cho HY, Jung SJ, Kim KR, Ro JY, et al. Carcinoma of mullerian origin presenting as colorectal cancer: a clinicopathologic study of 13 Cases. Ann Diagn Pathol 2011;15:12-8.
28. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005;11:63-70.
29. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26:2139-46.
30. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851-63.
31. Pio R, Ajona D, Lambris JD. Complement inhibition in cancer therapy. Semin Immunol 2013;25:54-64.
32. Seeber B, Sammel MD, Fan X, Gerton GL, Shaunik A, Chittams J, et al. Proteomic analysis of serum yields six candidate proteins that are differentially regulated in a subset of women with endometriosis. Fertil Steril 2010;93:2137-44.
33. Funamizu A, Fukui A, Kamoi M, Fuchinoue K, Yokota M, Fukuhara R, et al. Expression of natural cytotoxicity receptors on peritoneal fluid natural killer cell and cytokine production by peritoneal fluid natural killer cell in women with endometriosis. Am J Reprod Immunol 2014;71:359-67.
34. Itoh F, Komohara Y, Takaishi K, Honda R, Tashiro H, Kyo S, et al. Possible involvement of signal transducer and activator of transcription-3 in cell-cell interactions of peritoneal macrophages and endometrial stromal cells in human endometriosis. Fertil Steril 2013;99:1705-13.
35. Aslan C, Ak H, Askar N, Ozkaya AB, Ergenoglu AM, Yeniel AO, et al. Overexpression of complement C5 in endometriosis. Clin Biochem 2014;47:496-8.
36. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010;11:785-97.
37. Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. Cancer and the complement cascade. Mol Cancer Res 2010;8:1453-65.
38. Markiewski MM, De Angelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008;9:1225-35.
39. Rutkowski MJ, Sughrue ME, Kane AJ, Ahn BJ, Fang S, Parsa AT. The complement cascade as a mediator of tissue growth and regeneration. Inflamm Res 2010;59:897-905.
40. Nunez-Cruz S, Gimotty PA, Guerra MW, Connolly DC, Wu YQ, De Angelis RA, et al. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 2012;14:994-1004.
41. Britten CD. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother Pharmacol 2013;71:1395-409.
42. Patel SP, Kim KB. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. Expert Opin Investig Drugs 2012;21:531-9.
43. Eisenberg VH, Zolti M, Soriano D. Is there an association between autoimmunity and endometriosis? Autoimmun Rev 2012;11:806-14.
44. Lebovic DI, Mueller MD, Taylor RN. Immunobiology of endometriosis. Fertil Steril 2001;75:1-10.
45. Wu MY, Ho HN. The role of cytokines in endometriosis. Am J Reprod Immunol 2003;49:285-96.
46. Badawy SZ, Cuenca V, Stitzel A, Jacobs RD, Tomar RH. Autoimmune phenomena in infertile patients with endometriosis. Obstet Gynecol 1984;63:271-5.